CRIS Curis Inc · XNAS
0.57 -17.9% as of Nov 10, 13:55 ET
fans
What's happening Live detector signal Generated 00:51 ET
Share structure
Free float
1.9M
2026-08-19
Shares out
6.7M
latest detail
Market cap
$4.4M
at ref price
Short interest
54.4%
2026-10-30
Float rotation
0.49×
latest snapshot
20d dollar vol
$15.3M
baseline
Supply intelligence
Gap quality
squeeze-prone · 92
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
very tight float
detector reason
Supply factor
meaningful float rotation
detector reason
Supply factor
high short interest
detector reason

This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.

Filings and news
2026-11-10 13:55 ETSignalCuris Inc is down 17.9%, at 0.57, on $527.8K traded, 0.49× float rotation. Score 70. Primary driver: 48.7% float rotation. Supply intelligence: squeeze-prone · 92.
2026-11-068-KItem 3.01 — Notice of delisting or failure to satisfy listing rule SEC
2026-11-02DEF 14AProxy statement SEC
2026-10-198-KItem 1.01 — Entry into a material definitive agreement; Item 3.02 — Unregistered sales of equity securities +1 more SEC
2026-09-23 05:00 ETFDA / ClinicalLift Therapeutics Appoints Daniel Passeri as Chief Executive Officer News
2026-08-1410-QQuarterly report SEC
2026-08-12EFFECTPotential financing or dilution-related filing. SEC
2026-08-10S-1Potential financing or dilution-related filing. SEC
2026-07-06Split1-for-20 reverse split logged
2026-03-19 17:17 ETEarnings GuidanceCuris (CRIS) Q4 2025 Earnings Call Transcript News
2025-08-05 18:10 ETAnalyst RatingCuris (CRIS) Q2 Loss Narrows 66% News
2024-07-11 06:09 ETFDA / ClinicalVISTA Inhibitor Clinical Trials Drug Approval Insight - GlobeNewswire News
Latest detector signalscore 70
score 70